6 January 2020News UpdateLaunch new websiteNew year, new website...Read more 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more 11 September 2019News UpdateCergentis on track with product development of TLA-based targeted complete next generation sequencing on FFPE samples for cancer diagnosticsBy combining proximity ligation with improved targeting strategies, we are able to sequence genes of interest completely, over a large width of 100’s of kilobas...Read more 31 August 2019News UpdateNew appnote releasedCergentis released a new application note: "Complete locus sequencing and quality control of targeted genome editing". ...Read more 9 April 2019News UpdateCergentis releases two new application notes: improving QC in cell & gene therapy manufacturing with TLAOur Targeted Locus Amplification (TLA) technology has unique advantages in the quality control of transgenic and genetically engineered samples. TLA can assess ...Read more 5 March 2019News UpdateCergentis’ TLA technology and Genedata software: efficient in-house data analysis for CHO cell line developmentTLA is used in multiple stages in CHO cell line development, e.g. early stage clone selection, and enables the assessment of genetic stability of Master Cell Ba...Read more 2 October 2018News UpdateNew Glenmark paper: TLA and clonal derivation assessment of (CHO) cell linesGlenmark Pharmaceuticals describes the use of the TLA technology in the analytical assessment of clonal derivation of cell populations....Read more 13 September 2018News UpdateCergentis & Princess Máxima Center collaborate on MRD test development for leukaemia and solid tumoursCergentis & the Princess Máxima Center for pediatric oncology have initiated various collaborations for the design of sensitive & quantitative MRD and/or ctDNA ...Read more 13 June 2018News UpdateCergentis’ CEO invited to present TLA technology at ACTIP meeting in DusseldorfOn June 7, our CEO attended the ACTIP meeting in Dusseldorf where he had the privilege of being invited to give a presentation...Read more 15 November 2017News UpdateMeet us at the Cell Therapy Manufacturing & Gene Therapy Congress next monthCergentis is sponsor of the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam between December 5-7....Read more
© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.